Log in
Enquire now
‌

Ferrologix, Inc. SBIR Phase II Award, September 2020

A SBIR Phase II contract was awarded to Ferrologix Inc in September, 2020 for $920,268.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1918069
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
Ferrologix Inc
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
4R44CA228844-020
Award Phase
Phase II0
Award Amount (USD)
920,2680
Date Awarded
September 8, 2020
0
End Date
August 31, 2022
0
Abstract

Project Summary Therapies based on Chimeric Antigen Receptors (CAR) or T Cell Receptors (TCR) have shown incredible potential as personalized immunotherapies for cancer patients which involves enrichment and modification of immune cells to express targeting moieties against cancer cells. Studies have shown that deriving therapies from well-defined sets of cell subpopulations have superior potency and sustained reaction compared to therapies derived from heterogenous populations and represents a direction of growth for the cell therapy industry in order to take on more complex and elusive diseases. Unfortunately, current cell purification platforms, such as flow cytometry and magnetic assisted cell sorting, struggle to balance the throughput and quantitative power needed to precisely enrich the target cell subpopulations for scalable manufacture of precision immunotherapies. We reasoned that a tool that balanced quantitative cell sorting capacity with high throughput operation would alleviate this bottleneck and enable development of more nuanced and multifaceted therapies. With preliminary studies, we demonstrated a prototype platform based on a technique called ratcheting cytometry that can achieve quantitative sorting of target cell subpopulations by multiplexing on magnetic bead strength. In this proposal, we aim to develop a high throughput batch purification cartridge and instrument that can precisely enrich target cell subpopulations directly from complex biomatrix samples, such as a leukopak or apheresis product. In phase I we will focus on optimizing the quantitative separation parameters to maximize capture and purity of multiple target cell types. In phase II we will focus on scaling the platform to meet with cell manufacturing throughput requirements.Project Narrative The goal of this project is to develop a cell purification platform to enrich specific cell types from complex biomatrices which are needed to manufacture precision cancer immunotherapies. Current technologies cannot balance quantitative/multiparameter cell sorting capacity with high throughput operation. Our platform technology can achieve quantitative cell sorting but can be easily scaled to manufacturing operation.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Ferrologix, Inc. SBIR Phase II Award, September 2020

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.